Healthcare
MedinCell S.A.(MDCLF)
Live Price
Offline$34.39
+0.00% today
1Y Change
+392.98%
Window
Jun 26, 2025 β Jun 18, 2026
- Market Cap
- $890.00M
- Revenue Growth
- +178.8%
- EPS Growth
- +28.4%
- Dividend Yield
- 0.0%
Coverage: 246 bars Β· Jun 26, 2025 β Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
MedinCell S.A. (MDCLF) is a Healthcare stock with a market cap of $890.00M and listed on OTC. The stock last traded around $34.39 and up 393.0% across the available one-year price window (Jun 26, 2025 β Jun 18, 2026). Baseline metrics include revenue growth of +178.8%, EPS growth of +28.4%, a dividend yield of 0.0%. What stands out right now is revenue +178.8%, EPS +28.4%, free cash flow +235.8% with operating margin -45.0% and ROIC -18.8%. Valuation already assumes a fairly strong business story at price/sales 32.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines MDCLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+178.8% vs +7.6% peer median
Operating Margin
Below sector median
-45.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 16, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +178.8% and EPS at +28.4%, with operating margin around -45.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 16, 2026 | β | +0.0% | β | β |
2025 Dec 9, 2025 | -85.7% | +0.0% | +0.0% | +0.0% |
2025 Jun 17, 2025 | +70.7% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
MDCLF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MDCLF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MDCLF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MDCLF and SPY.
Company Overview
MedinCell S.A.
Other OTC
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.
- Leadership
- Christophe Douat
- IPO Date
- Jan 5, 2021
- Employees
- 131
- Street Address
- 3 rue des Frères Lumière
- Mailing
- Jacou, 34830
- Region
- Jacou, FR
- Reporting Currency
- USD
- Investor Line
- 33 4 67 02 13 67
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 32.0
- Price/Book
- β
Growth
- Revenue
- +178.8%
- EPS
- +28.4%
- Free Cash Flow
- +235.8%
Profitability
- Gross Margin
- 58.1%
- Operating Margin
- -45.0%
- Net Margin
- -72.0%
- ROE
- 84.9%
- ROIC
- -18.8%
Balance Sheet
- Debt/Equity
- β
- Current Ratio
- 2.88
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.